Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-06-30

Study Completion Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study was undertaken to assess the immunogenicity and safety of a booster dose of a live attenuated chimeric Japanese Encephalitis vaccine (JE-CV) after primary vaccination with SA14-14-2 in Thai children aged 1 to \<5 years. In addition, to assess the impact of the duration interval after primary vaccination on subsequent booster response.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine

NCT02602652

Japanese Encephalitis

COMPLETED NA

A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers

NCT01092507

Encephalitis Japanese Encephalitis

COMPLETED PHASE3

Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children

NCT00621764

Japanese Encephalitis Hepatitis A

COMPLETED PHASE2

Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea

NCT01900444

Japanese Encephalitis

COMPLETED PHASE3

Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers

NCT01396512

Japanese Encephalitis Japanese Encephalitis Virus Disease

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The subject will receive one booster dose of IMOJEV with hepatitis A vaccine (inactivated vaccine of GlaxoSmithKline) as concomitant vaccine. Blood samples will be collected to assess for Japanese Encephalitis Neutralizing Antibody at baseline (pre-vaccination) and 4 week post -vaccination.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Encephalitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Imojev

Live attenuated chimeric Japanese Encephalitis vaccine, 0.5 mL dose containing ≥ 4.0 log10 plaque forming units (PFU) administered via the subcutaneous route into the left thigh and Simultaneous administration of Inactivated Hepatitis A vaccine, 0.5 mL liquid dose for intramuscular injection administered via the intramuscular route into the right thigh

Group Type EXPERIMENTAL

Live attenuated chimeric Japanese Encephalitis vaccine

Intervention Type BIOLOGICAL

0.5 mL dose containing ≥ 4.0 log10 plaque forming units (PFU) administered via the subcutaneous route into the left thigh

Inactivated Hepatitis A vaccine

Intervention Type BIOLOGICAL

0.5 mL liquid dose for intramuscular injection administered via the intramuscular route into the right thigh

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Live attenuated chimeric Japanese Encephalitis vaccine

0.5 mL dose containing ≥ 4.0 log10 plaque forming units (PFU) administered via the subcutaneous route into the left thigh

Intervention Type BIOLOGICAL

Inactivated Hepatitis A vaccine

0.5 mL liquid dose for intramuscular injection administered via the intramuscular route into the right thigh

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Imojev Havrix

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children aged 1 to \<5 years on the day of inclusion
* History of received 1 dose of CD.JEVAX at 9-15 months prior to enrollment
* In good general health at the time of inclusion
* Provision of informed consent by the parent(s) or legal guardian(s)

Exclusion Criteria

* Receipt of blood or blood products in the past 3 months
* Acute febrile illness on the day of vaccination (Body Temperature ≥ 38 ◦C)
* Previous receipt of 2 doses of any vaccine against JE virus
* Known hypersensitivity to any of the vaccine components
* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination
* Planned receipt of any live attenuated vaccine within 4 weeks following the trial vaccination

Minimum Eligible Age

1 Year

Maximum Eligible Age

5 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes